CORRECTION: Apellis Pharmaceuticals Q2 2024 GAAP EPS $(0.30) Beats $(0.32) Estimate, Sales $199.70M Beat $191.51M Estimate
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals reported Q2 2024 GAAP EPS of $(0.30), beating the estimate of $(0.32). Sales were $199.70M, surpassing the $191.51M estimate.
August 01, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals reported better-than-expected Q2 2024 results with GAAP EPS of $(0.30) beating the $(0.32) estimate and sales of $199.70M surpassing the $191.51M estimate.
The better-than-expected earnings and sales figures are likely to positively impact Apellis Pharmaceuticals' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100